Literature DB >> 3958779

PCNU in the treatment of recurrent medulloblastoma and ependymoma--a POG Study.

A H Ragab, P Burger, S Badnitsky, J Krischer, J Van Eys.   

Abstract

Seventeen children with recurrent medulloblastoma and ependymoma received PCNU (100 mg/m2) in a Phase II trial. Response was evaluated by CAT scan. There were no responses. Administration of PCNU was associated with significant thrombocytopenia.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 3958779     DOI： 10.1007/bf00165583

Source DB:  PubMed          Journal:  J Neurooncol        ISSN： 0167-594X            Impact factor:   4.130


  4 in total

1.  Effectiveness of the nitrosoureas as a function of their lipid solubility in the chemotherapy of experimental rat brain tumors.

Authors:  V A Levin; P Kabra
Journal:  Cancer Chemother Rep       Date:  1974 Nov-Dec

2.  Phase II trial of PCNU in children with recurrent brain tumors and Hodgkin's disease.

Authors:  C Hancock; J Allen; C T Tan
Journal:  Cancer Treat Rep       Date:  1984-02

3.  PCNU treatment for recurrent malignant gliomas.

Authors:  V A Levin; K J Resser; L McGrath; P Vestnys; S Nutik; C B Wilson
Journal:  Cancer Treat Rep       Date:  1984 Jul-Aug

4.  A phase II trial of 1-(2-chloroethyl)-3-(2,6-dioxo-3-piperidyl)-1-nitrosourea (PCNU, NSC 95466) in recurrent malignant brain tumors.

Authors:  L G Feun; D J Stewart; M E Leavens; M A Burgess; N Savaraj; R S Benjamin; G P Bodey
Journal:  J Neurooncol       Date:  1983       Impact factor: 4.130
  4 in total
  5 in total

Review 1.  Salvage chemotherapy for metastatic and recurrent ependymoma of childhood.

Authors:  Eric Bouffet; Michael Capra; Ute Bartels
Journal:  Childs Nerv Syst       Date:  2009-04-10       Impact factor: 1.475

2.  PCNU and recurrent childhood brain tumors.

Authors:  J C Allen; C Hancock; R Walker; C Tan
Journal:  J Neurooncol       Date:  1987       Impact factor: 4.130

3.  Expression of estramustine-binding protein in ependymomas and in human and developing rat ependymal cells.

Authors:  A T Bergenheim; M Hartman; J Bergh; P A Ridderheim; R Henriksson
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Superiority of PCNU over AZQ in the treatment of primary brain tumors: results of a prospective randomized trial (81-20) by the Brain Tumor Study Group.

Authors:  M G Malkin; S B Green; D P Byar; T A Strike; P C Burger; F S Vogel; D A Pistenmaa; M S Mahaley; J Ransohoff; W R Shapiro
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

Review 5.  Childhood ependymoma: a systematic review of treatment options and strategies.

Authors:  Jacques Grill; Chastagner Pascal; Kalifa Chantal
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.